C4 Therapeutics Inc is trading at $3.85 (+7.2%), rebounding after a sharp multi-session pullback following its late-May/early-June rally.
- The stock has recently exhibited high volatility and a high-beta profile, with previous downward pressure attributed to profit-taking rather than shifts in underlying fundamentals.
- With no fresh company-specific news or analyst rating changes reported on June 9, 2026, the early bounce appears to be a technical recovery within a volatile trading range.